Develops drugs for immune-mediated diseases.
Jun 2026Revenue $28.7M/yrExpenses $211M/yr
No trendCash runway ≈ 2.8 years from Jun 2026
Figures by year
When will Monte Rosa Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $28.7M and expenses $211M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $124M | $178M | −$54.2M |
| Dec 2024 | $75.6M | $157M | −$81.1M |
| Dec 2023 | $0.00 | $143M | −$143M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.